Next-generation sequencing may help identify patients with smoldering multiple myeloma at high risk for disease progression.

Conferences

Clinicians are now trying to treat multiple myeloma similar to leukemia, according to George Somlo, MD, who discussed treatment regimens at the 2016 National Comprehensive Cancer Network (NCCN) Annual Congress on Hematologic Malignancies.

------

Read More

Since 2015, the US Food and Drug Administration (FDA) has approved 4 new therapies for the treatment of multiple myeloma: panobinostat, daratumumab, ixazomib, and elotuzumab.

Read More

Autologous stem cell transplantation (ASCT) is still the preferred treatment of choice for patients under the age of 65 years with newly diagnosed multiple myeloma (NDMM), according to early results from a phase 3 trial presented during a press briefing ahead of the 2016 American Society of Clinical Oncology Annual Meeting (June 3-7, 2016; Chicago, IL).

Read More

News

Next-generation sequencing may help identify patients with smoldering multiple myeloma at high risk for disease progression.

A comparative effectiveness study analyzed response to anemia supportive treatment for patients with multiple myeloma or lymphoma, published in Supportive Care in Cancer (online November 7, 2017; doi:10.1007/s00520-017-3948-5).

Read More

A recent study confirmed that administering a higher dosage once-weekly of a common therapy for relapsed or refractory multiple myeloma improves progression-free survival (PFS) by 3.6 months, compared with twice-weekly administration of a lower dosage.

Read More

Researchers developed a novel gene signature that has prognostic value in patients with multiple myeloma who are treated with immunomodulatory derivatives (IMiDs), according to research published in The Lancet Hematology (September 2017;4[9]:e443-e451).

Read More

Quiz

According to a recent study, maintenance therapy with which agent prolongs time to remission after autologous stem cell transplantation in multiple myeloma?

Research in Review

According to recent research presented at ASCO, adding which targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone is a safe and efficacious alternative to ASCT for patients with multiple myeloma?

-----

A. Daratumumab

B. Elotuzumab 

C. Pembrolizumab

D. Nivolumab

-----

Read More

Targeted therapy against a particular protein has the potential to improve outcomes and fracture-free survival for patients with multiple myeloma, according to research that will be presented at the 2017 ASCO Annual Meeting (June 2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Adult patients with multiple myeloma who receive a high-dose chemotherapy regimen plus autologous stem-cell transplantation improve their median progression-free survival (PFS) by 14 months compared with patients who receive chemotherapy alone, according to a study published in the New England Journal of Medicine (April 6, 2017;376:1311-1320).

-----

Read More

Single agent daratumumab may serve as a more cost-effective treatment strategy than pomalidomide for patients with refractory multiple myeloma.

-----

Related Content

Read More

Subscribe to Hematologic Malignancies